List of works - Hernan Carol

A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921)

scientific article published on 18 February 2019

AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia

scientific article

Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant.

scientific article published on 14 June 2016

Bioluminescence Imaging Enhances Analysis of Drug Responses in a Patient-Derived Xenograft Model of Pediatric ALL.

scientific article published on 24 January 2017

Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts

scientific article

Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia

scientific article

Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer.

scientific article published on 30 March 2011

Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program

scientific article

Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia

scientific article

Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program.

scientific article published on 30 May 2016

Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program

scientific article

Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program.

scientific article

Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling

scientific article published on 16 August 2011

Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program.

scientific article

Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program

scientific article published on 18 November 2014

Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program

scientific article published on 16 June 2011

Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program.

scientific article published on 2 November 2011

Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program

scientific article published on June 2008

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program

scientific article

Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program

scientific article

Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program

scientific article published on October 2009

Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program

scientific article published on February 2010

Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program

scientific article

Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program.

scientific article

Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program

scientific article published on June 2008

Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.

scientific article

Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.

scientific article published on 27 September 2014

Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.

scientific article

Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program.

scientific article published on 21 September 2016

Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.

scientific article

Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program

scientific article

Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program

scientific article

Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program.

scientific article published on December 2009

Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program.

scientific article

Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program

scientific article

Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program

scientific article published on December 2010

Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program

scientific article

Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.

scientific article

Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program.

scientific article

Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program.

scientific article published on January 2008

Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program.

scientific article published on September 2009

Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program.

scientific article published on 15 September 2011

Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program.

scientific article published on 27 October 2016

Initial testing of aplidin by the pediatric pre-clinical testing program.

scientific article published on September 2009

Initial testing of lenalidomide by the pediatric preclinical testing program

scientific article published on 25 February 2011

Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program

scientific article

Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program

scientific article

Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).

scientific article

Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program.

scientific article

Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.

scientific article published on 19 October 2011

Initial testing of topotecan by the pediatric preclinical testing program.

scientific article

Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program.

scientific article

Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts.

scientific article

Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program.

scientific article published on July 2008

Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program

scientific article

Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.

scientific article

Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program.

scientific article published on 18 November 2011

Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program.

scientific article

The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.

scientific article published on 20 February 2013

The pediatric preclinical testing program: description of models and early testing results.

scientific article published in December 2007

Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.

scientific article

List of works by Hernan Carol

A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921)

AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia

Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant.

Bioluminescence Imaging Enhances Analysis of Drug Responses in a Patient-Derived Xenograft Model of Pediatric ALL.

Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts

Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia

Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer.

Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program

Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia

Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program.

Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program

Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program.

Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling

Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program.

Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program

Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program

Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program.

Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program

Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program

Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program

Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program

Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program

Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program.

Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program

Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.

Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.

Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.

Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program.

Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.

Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program

Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program

Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program.

Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program.

Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program

Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program

Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program

Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.

Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program.

Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program.

Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program.

Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program.

Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program.

Initial testing of aplidin by the pediatric pre-clinical testing program.

Initial testing of lenalidomide by the pediatric preclinical testing program

Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program

Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program

Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).

Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program.

Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.

Initial testing of topotecan by the pediatric preclinical testing program.

Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program.

Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts.

Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program.

Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program

Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.

Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program.

Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program.

The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.

The pediatric preclinical testing program: description of models and early testing results.

Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.